Clinical trial
Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive…
NCT00466726 · Gruppo Italiano Malattie EMatologiche dell'Adulto, Other · Completed
Key facts
| NCT number | NCT00466726 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia |
| Official title | Phase II Multicenter Study of P210-B3A2 Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients in Complete Cytogenetic Response With Persistent Molecular Residual Disease During Imatinib Treatment |
| Acronym | CML0206 |
| Lead sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine, sargramostim |
| Enrollment | 57 |
| Start date | Mar 1, 2007 |
| Primary completion | Jul 1, 2014 |
| Completion | Jul 1, 2014 |
| First posted | Apr 27, 2007 |
| Last update posted | Aug 28, 2018 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: